An in-depth analysis of lorlatinib/lorlatinib: mechanism of action and clinical research progress

Lorlatinib/Lorlatinib is a new generation of small molecule tyrosine kinase inhibitors (TKI). As a novel, reversible ATP competitive inhibitor, it mainly inhibits ALK (anaplastic lymphoma kinase) and ROS1. This drug achieves therapeutic effects by interrupting the ALK and ROS1 signaling pathways. In Europe and the United States, lorlatinib has been widely used to treat ALK-positive non-small cell lung cancer. It is worth mentioning that lorlatinib also shows significant therapeutic effects in patients who have passed the blood-brain barrier and developed brain metastases.

Studies in animal models have further confirmed that compared with alectinib, lorlatinib has more advantages in the treatment of central nervous system lesions. Lorlatinib is a tyrosine kinase inhibitor (TKI) with a clear targeted mechanism of action. Tyrosine kinases are proteins used to transmit growth signals between cells and play an important role as chemical messengers. By blocking these signals, lorlatinib helps slow or stop cancer growth.

Larlatinib may be an effective treatment option for patients whose cancer has recurred or worsened despite having been previously treated with ALK-targeting drugs. However, before starting treatment, doctors will conduct detailed cancer cell testing to look for changes in proteins and genes, especially changes in the ALK gene, to determine whether the patient is a candidate for lorlatinib treatment.

Clinical research data show that at any time point observed, the cumulative incidence of central nervous system progression and non-central nervous system progression in patients in the alectinib group was significantly lower than that in the crizotinib group. These findings provide strong clinical evidence for the application of lorlatinib in the treatment of lung cancer.